LivaNova Publishes Results In Neuromodulation: Technology At The Neural Interface Regarding Its CORE-VNS Trial Of Its VNS Therapy Devices

Benzinga · 2d ago

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy (DRE). The article, "CORE-VNS Seizure and Non-Seizure 36 Month Outcomes in People with Drug-resistant Epilepsy,"1 reports findings from the full international CORE-VNS cohort, providing one of the most extensive evaluations of long-term outcomes associated with contemporary VNS Therapy in people with DRE.